These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37924026)

  • 1. Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma.
    Drouyer A; Beaussire L; Jorda P; Leheurteur M; Guillemet C; Berghian A; Georgescu D; Di Fiore F; Perdrix A; Clatot F
    BMC Cancer; 2023 Nov; 23(1):1061. PubMed ID: 37924026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Sueta A; Tomiguchi M; Murakami K; Omoto Y; Iwase H
    BMC Cancer; 2017 Nov; 17(1):786. PubMed ID: 29166868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients.
    Allouchery V; Beaussire L; Perdrix A; Sefrioui D; Augusto L; Guillemet C; Sarafan-Vasseur N; Di Fiore F; Clatot F
    Breast Cancer Res; 2018 May; 20(1):40. PubMed ID: 29769099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.
    Clatot F; Perdrix A; Augusto L; Beaussire L; Delacour J; Calbrix C; Sefrioui D; Viailly PJ; Bubenheim M; Moldovan C; Alexandru C; Tennevet I; Rigal O; Guillemet C; Leheurteur M; Gouérant S; Petrau C; Théry JC; Picquenot JM; Veyret C; Frébourg T; Jardin F; Sarafan-Vasseur N; Di Fiore F
    Oncotarget; 2016 Nov; 7(46):74448-74459. PubMed ID: 27801670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
    Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
    Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.
    Wang P; Bahreini A; Gyanchandani R; Lucas PC; Hartmaier RJ; Watters RJ; Jonnalagadda AR; Trejo Bittar HE; Berg A; Hamilton RL; Kurland BF; Weiss KR; Mathew A; Leone JP; Davidson NE; Nikiforova MN; Brufsky AM; Ambros TF; Stern AM; Puhalla SL; Lee AV; Oesterreich S
    Clin Cancer Res; 2016 Mar; 22(5):1130-7. PubMed ID: 26500237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.
    Yanagawa T; Kagara N; Miyake T; Tanei T; Naoi Y; Shimoda M; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2017 Jun; 163(2):231-240. PubMed ID: 28283903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single droplet digital PCR for ESR1 activating mutations detection in plasma.
    Jeannot E; Darrigues L; Michel M; Stern MH; Pierga JY; Rampanou A; Melaabi S; Benoist C; Bièche I; Vincent-Salomon A; El Ayachy R; Noret A; Epaillard N; Cabel L; Bidard FC; Proudhon C
    Oncogene; 2020 Apr; 39(14):2987-2995. PubMed ID: 32042112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis.
    Urso L; Vernaci G; Carlet J; Lo Mele M; Fassan M; Zulato E; Faggioni G; Menichetti A; Di Liso E; Griguolo G; Falci C; Conte P; Indraccolo S; Guarneri V; Dieci MV
    Front Oncol; 2021; 11():625636. PubMed ID: 33777770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.
    Clatot F; Perdrix A; Beaussire L; Lequesne J; Lévy C; Emile G; Bubenheim M; Lacaille S; Calbrix C; Augusto L; Guillemet C; Alexandru C; Fontanilles M; Sefrioui D; Burel L; Guénot S; Richard D; Sarafan-Vasseur N; Di Fiore F
    Breast Cancer Res; 2020 May; 22(1):56. PubMed ID: 32466779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA.
    Sundaresan TK; Dubash TD; Zheng Z; Bardia A; Wittner BS; Aceto N; Silva EJ; Fox DB; Liebers M; Kapur R; Iafrate J; Toner M; Maheswaran S; Haber DA
    Breast Cancer Res Treat; 2021 Jul; 188(1):43-52. PubMed ID: 34101078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
    Transl Res; 2015 Dec; 166(6):540-553.e2. PubMed ID: 26434753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
    Fribbens C; Garcia Murillas I; Beaney M; Hrebien S; O'Leary B; Kilburn L; Howarth K; Epstein M; Green E; Rosenfeld N; Ring A; Johnston S; Turner N
    Ann Oncol; 2018 Jan; 29(1):145-153. PubMed ID: 29045530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Omoto Y; Iwase H
    Transl Oncol; 2017 Oct; 10(5):766-771. PubMed ID: 28778025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.
    Chandarlapaty S; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Voi M; Gnant M; Hortobagyi G; Baselga J; Moynahan ME
    JAMA Oncol; 2016 Oct; 2(10):1310-1315. PubMed ID: 27532364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Implications of Monitoring ESR1 Mutations by Circulating Tumor DNA in Estrogen Receptor Positive Metastatic Breast Cancer: A Pilot Study.
    Li X; Lu J; Zhang L; Luo Y; Zhao Z; Li M
    Transl Oncol; 2020 Feb; 13(2):321-328. PubMed ID: 31877464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer.
    Sefrioui D; Perdrix A; Sarafan-Vasseur N; Dolfus C; Dujon A; Picquenot JM; Delacour J; Cornic M; Bohers E; Leheurteur M; Rigal O; Tennevet I; Thery JC; Alexandru C; Guillemet C; Moldovan C; Veyret C; Frebourg T; Di Fiore F; Clatot F
    Int J Cancer; 2015 Nov; 137(10):2513-9. PubMed ID: 25994408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole.
    Gyanchandani R; Kota KJ; Jonnalagadda AR; Minteer T; Knapick BA; Oesterreich S; Brufsky AM; Lee AV; Puhalla SL
    Oncotarget; 2017 Sep; 8(40):66901-66911. PubMed ID: 28978004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.